Valuation: Abpro Corporation

Market Cap 2.08M 1.85M 1.73M 1.57M 2.97M 200M 2.99M 20.89M 8.09M 102M 7.81M 7.64M 328M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 2.16M 1.92M 1.79M 1.63M 3.08M 208M 3.11M 21.69M 8.4M 106M 8.11M 7.94M 341M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.08M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.20%-0.59%+52.63%+128.54% 43.39B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2024 2025
Net sales 183K 163K 152K 138K 261K 17.59M 263K 1.84M 712K 8.99M 687K 672K 28.86M -
Net income -7.23M -6.43M -6M -5.47M -10.31M -695M -10.41M -72.58M -28.12M -355M -27.15M -26.56M -1.14B -2.89M -2.57M -2.4M -2.19M -4.12M -278M -4.16M -29.02M -11.25M -142M -10.86M -10.62M -456M
Net Debt 478K 425K 396K 361K 681K 45.95M 688K 4.8M 1.86M 23.49M 1.79M 1.76M 75.39M 80K 71.08K 66.34K 60.47K 114K 7.69M 115K 803K 311K 3.93M 300K 294K 12.62M
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-